Published in Qual Life Res on January 28, 2010
The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace (2014) 0.87
Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial. Trials (2015) 0.81
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart (2014) 0.81
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics (2014) 0.79
Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece. Clinicoecon Outcomes Res (2016) 0.75
The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation. J Atr Fibrillation (2011) 0.75
Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model. Clinicoecon Outcomes Res (2013) 0.75
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland. Eur J Health Econ (2012) 0.75
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. BMJ (2013) 2.58
Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease: epicardial breakthrough. Circulation (2010) 2.56
Transthoracic tissue Doppler imaging of the atria: a novel method to determine the atrial fibrillation cycle length. J Cardiovasc Electrophysiol (2006) 2.05
Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol (2011) 1.91
Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90
Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace (2008) 1.68
Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67
Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J (2011) 1.60
Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace (2010) 1.59
Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57
Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J (2008) 1.57
Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. Heart Rhythm (2012) 1.53
Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace (2013) 1.43
Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol (2007) 1.42
Adenosine testing after second-generation balloon devices (cryothermal and laser) mediated pulmonary vein ablation for atrial fibrillation. J Interv Card Electrophysiol (2014) 1.29
Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum (2002) 1.26
Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol (2005) 1.25
Impact of hybrid procedure on P wave duration for atrial fibrillation ablation. J Interv Card Electrophysiol (2015) 1.24
Pregnancy and birth outcomes of women with intellectual disability in Sweden: a national register study. Acta Obstet Gynecol Scand (2012) 1.23
The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol (2009) 1.21
The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med (2013) 1.20
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace (2013) 1.16
Newborns of mothers with intellectual disability have a higher risk of perinatal death and being small for gestational age. Acta Obstet Gynecol Scand (2012) 1.15
Activation of Akt (PKB) and suppression of FKHRL1 in mouse and rat oocytes by stem cell factor during follicular activation and development. Dev Biol (2005) 1.14
Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sci (2004) 1.09
Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ (2006) 1.05
Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ (2006) 1.05
Minimally invasive surgical treatment of lone atrial fibrillation: early results of hybrid versus standard minimally invasive approach employing radiofrequency sources. Int J Cardiol (2012) 1.05
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J (2013) 1.01
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol (2005) 1.01
Transmural conduction is the predominant mechanism of breakthrough during atrial fibrillation: evidence from simultaneous endo-epicardial high-density activation mapping. Circ Arrhythm Electrophysiol (2013) 1.00
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil (2004) 1.00
Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction. J Am Coll Cardiol (2005) 1.00
Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J (2009) 1.00
Validity of the hospital anxiety and depression scale for use with patients with noncardiac chest pain. Psychosomatics (2003) 0.95
Increased uncoupling protein 3 content does not affect mitochondrial function in human skeletal muscle in vivo. J Clin Invest (2003) 0.95
Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ (2006) 0.94
Long term health care consumption and cost expenditure in systolic heart failure. Eur J Intern Med (2012) 0.92
Is brain natriuretic peptide production decreased in obese subjects? J Am Coll Cardiol (2006) 0.91
Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ (2006) 0.87
Information and knowledge about Down syndrome among women and partners after first trimester combined testing. Acta Obstet Gynecol Scand (2015) 0.87
The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. J Cardiovasc Electrophysiol (2010) 0.86
The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil (2009) 0.86
Increased incidence of malignancies in Sweden after the Chernobyl accident--a promoting effect? Am J Ind Med (2006) 0.86
Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey. Clin Cardiol (2010) 0.85
Facts first, then reaction--expectant fathers' experiences of an ultrasound screening identifying soft markers. Midwifery (2011) 0.83
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost (2012) 0.83
Comprehensive upstream treatment for atrial fibrillation, when and how? Europace (2009) 0.83
Use and underuse of oral anticoagulation for stroke prevention in atrial fibrillation: old and new paradigms. Semin Thromb Hemost (2009) 0.83
Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q). Health Qual Life Outcomes (2009) 0.83
Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. Clin Ther (2012) 0.82
Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. Am J Obstet Gynecol (2009) 0.82
Characteristics, management and prognosis of elderly patients in the Euro Heart Survey on atrial fibrillation. Aging Clin Exp Res (2012) 0.82
Identification of Rotors during Human Atrial Fibrillation Using Contact Mapping and Phase Singularity Detection: Technical Considerations. IEEE Trans Biomed Eng (2016) 0.82
Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Curr Med Res Opin (2008) 0.81
Left ventricular three-dimensional quadripolar lead acute clinical study: the LILAC study. Pacing Clin Electrophysiol (2015) 0.80
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Clin Ther (2007) 0.80
Fetal ultrasound examination and assessment of genetic soft markers in Sweden: are ethical principles respected? Acta Obstet Gynecol Scand (2015) 0.80
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ (2005) 0.80
Economic evaluation of FE(NO) measurement in diagnosis and 1-year management of asthma in Germany. Respir Med (2007) 0.80
Midwives' knowledge of, attitudes towards and experiences of caring for women with intellectual disability during pregnancy and childbirth: a cross-sectional study in Sweden. Midwifery (2013) 0.80
Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes. Heart (2008) 0.79
Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. Value Health (2009) 0.79
Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ (2006) 0.79
Ultrasonographic fetal soft markers in a low-risk population: prevalence, association with trisomies and invasive tests. Acta Obstet Gynecol Scand (2014) 0.78
Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. Pharmacoeconomics (2012) 0.77
Implementation of combined ultrasound and biochemistry for risk evaluation of chromosomal abnormalities during the first trimester in Sweden. Acta Obstet Gynecol Scand (2014) 0.77
Identification of Rotors during Human Atrial Fibrillation using Contact Mapping and Phase Singularity Detection: Technical Considerations. IEEE Trans Biomed Eng (2016) 0.76
The value of cardiovascular hospitalization as an endpoint for clinical atrial fibrillation research. Europace (2011) 0.76
Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs. Cerebrovasc Dis (2010) 0.76
Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm (2011) 0.76
Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol (2011) 0.76
Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model. Clinicoecon Outcomes Res (2013) 0.75
When predicting atrial fibrillation, think 'scene of calamity'! Europace (2012) 0.75
Risk of malignancies in relation to terrestrial gamma radiation in a Swedish population cohort. Sci Total Environ (2010) 0.75
The impact of atrial fibrillation on quality of life of the elderly: the calm before the storm? Europace (2012) 0.75
"Zooming in" to new horizons: conduction abnormalities and other research perspectives in atrial fibrillation. Heart Rhythm (2009) 0.75
Lactate: panicking doctor or panicking patient? BMJ Case Rep (2010) 0.75
A Cluster-Randomized Controlled Trial Evaluating the Effectiveness and Cost-Effectiveness of Tobacco Cessation on Prescription in Swedish Primary Health Care: A Protocol of the Motivation 2 Quit (M2Q) Study. JMIR Res Protoc (2016) 0.75
[Good reasons for considering new management models in health care]. Lakartidningen (2014) 0.75
Erratum to: impact of hybrid procedure on P wave duration for atrial fibrillation ablation. J Interv Card Electrophysiol (2015) 0.75
Twin-twin transfusion syndrome and fetal medicine centers. Acta Obstet Gynecol Scand (2013) 0.75
Seeing is believing: unmasking left atrial appendage activity recorded in the left superior pulmonary vein without stimulation. J Cardiovasc Electrophysiol (2010) 0.75
The Euro Heart Survey program: what's in it for nurses? Prog Cardiovasc Nurs (2007) 0.75
Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial. Can J Cardiol (2013) 0.75
Extracardiac ice formation during cryoballoon technique for atrial fibrillation. Heart Rhythm (2009) 0.75
Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic. Thromb Res (2012) 0.75
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland. Eur J Health Econ (2012) 0.75